Clinical Trials
18 trialsNCT06598371 2026-05-20
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07591649 2026-05-19
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Masonic Cancer Center, University of Minnesota
Phase 1/2 Recruiting
NCT06158828 2026-05-05
ABCD-NK
Washington University School of Medicine
Phase 1/2 Recruiting
NCT06961357 2026-03-31
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT07255664 2025-12-08
ProbeTILity
Curacell Holding AB
Phase 1/2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT06532799 2024-11-12
BAH250
Essen Biotech
Phase 1/2 Recruiting
NCT06532812 2024-11-12
BAH249
Essen Biotech
Phase 1/2 Recruiting
NCT06530303 2024-11-05
BAH248
Essen Biotech
Phase 1/2 Recruiting
NCT06640582 2024-11-05
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT06538012 2024-10-15
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT03658785 2024-08-13
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
Phase 1/2 Recruiting
NCT04729543 2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2 Recruiting
NCT05981001 2023-08-08
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT05981014 2023-08-08
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting